Exploiting new targets for old bones
โ
Clifford J Rosen
๐
Article
๐
2010
๐
American Society for Bone and Mineral Research
๐
English
โ 49 KB
A fter alendronate was approved for the treatment of postmenopausal osteoporosis, expectations rose that new therapies would be developed to cure this debilitating disease. Public and private collaborations pushed the envelope to discover ''druggable'' targets in the skeletal remodeling unit. Initia